We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Observational Pilot Study of 18F-Sodium Fluoride (Na18F) Whole Body Positron Emission Tomography (PET) Scans for Imaging Bone

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2014 by AHS Cancer Control Alberta.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: June 17, 2009
Last Update Posted: October 3, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AHS Cancer Control Alberta
This study is being done to provide an alternative to bone scanning with technetium-99m (99mTc) labelled diphosphonates, and to document the safety of {18F}-Sodium Fluoride (Na18F) as a Positron Emission Tomography (PET) imaging radiopharmaceutical. Since the current availability of 99mTc was severely reduced because of the Chalk River shut down, alternative approaches to done scanning are needed. PET imaging with Na18F is one alternative approach to providing this critical clinical service.

Condition Intervention
Bone Scan Other: 18F-Sodium Fluoride (Na18F)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational Pilot Study of 18F-Sodium Fluoride (Na18F) Whole Body PET Scans in Patients for Whom 99m Tc MDP Bone Scans Would Normally be Indicated.

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • Establish the feasibility of using locally produced 18F-Sodium Fluoride for PET bone scans as a substitute for 99mTc MPD [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Demonstrate the safety of 18F-Sodium Fluoride by documentation of adverse events. [ Time Frame: 1 year ]

Estimated Enrollment: 9999
Study Start Date: June 2009
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1 Other: 18F-Sodium Fluoride (Na18F)
200-400 MBq/injection, up to 4 doses of Na18F will be permitted per patient as part of acceptable disease assessment.

Detailed Description:
18F-Sodium Fluoride (Na18F) PET imaging is a nuclear medicine procedure, and its principal radiopharmaceutical, Na18F, has been used for scanning the skeleton for the spread of cancer for more that 30 years, but has not been approved by Health Canada because less expensive alternate drugs have been available (99mTc diphosphonates). Given the sudden and drastic change in the availability of 99mTc, an acceptable alternative for 99mTc-diphosphonates is needed as soon as possible.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   15 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients for whom 99mTc MDP bone scans would normally be indicated

Inclusion Criteria:

  • Male or female patient for whom 99mTc-MDP bone scans would normally be indicated
  • If female of child-bearing potential and outside the window of 10 days since the last menstrual period, a negative serum or urine pregnancy test is required.
  • Age greater than or equal to 15 years
  • Able and willing to follow instructions and comply with the protocol
  • Provide written informed consent prior to participation in the study
  • If an oncology patient, the patient should have a Karnofsky Performance Scale Score greater than or equal to 50

Exclusion Criteria:

  • Nursing or pregnant females
  • Ages less than 15 years
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00922519

Contact: michelle Buyers 905-521-2100 ext 73450

Canada, Alberta
Calgary Foothills Medial Centre Recruiting
Calgary, Alberta, Canada
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada
Contact    905-521-2100      
University of Alberta Hospital Recruiting
Edmonton, Alberta, Canada
Canada, Manitoba
Health Sciences Centre Recruiting
Winnipeg, Manitoba, Canada
Canada, Ontario
Hamilton Health Sciences Recruiting
Hamilton, Ontario, Canada
St. Joseph's Healthcare Recruiting
Hamilton, Ontario, Canada
Thunder Bay Regional Health Sciences Centre Recruiting
Thunder Bay, Ontario, Canada
Centre for Addiction and Mental Health Recruiting
Toronto, Ontario, Canada
Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada
Sunnybrook Health Services Centre Recruiting
Toronto, Ontario, Canada
Sponsors and Collaborators
AHS Cancer Control Alberta
  More Information

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00922519     History of Changes
Obsolete Identifiers: NCT01065922
Other Study ID Numbers: DX-FLU-001/ethics 24765
First Submitted: June 15, 2009
First Posted: June 17, 2009
Last Update Posted: October 3, 2014
Last Verified: October 2014

Keywords provided by AHS Cancer Control Alberta:
Positron Emission Tomography
Sodium 18F-Fluoride
Bone Scan

Additional relevant MeSH terms:
Sodium Fluoride
Cariostatic Agents
Protective Agents
Physiological Effects of Drugs
Anti-Infective Agents, Local
Anti-Infective Agents